Yinyin Tech Secures Tens of Millions in Angel Funding to Build China's Leading Digital Collaboration Platform for Biopharmaceutical Research

VCBeat has learned that Shanghai Yanin Technology Co., Ltd. (hereinafter referred to as “Yanin Tech”) recently announced the completion of its angel financing round, raising tens of millions of yuan. This round was invested by Qiming Venture Partners. The proceeds will be used for product upgrades and commercial promotion of Yanin Zhiyan Cloud, a digital research collaboration platform for biopharmaceuticals, as well as for the application research and development of large AI models in the biopharmaceutical sector. Yanin Tech will establish a systematic online and offline marketing network and sales channels to serve innovative pharmaceutical companies and research institutions more precisely, helping researchers in the biopharmaceutical industry conduct scientific experiments and data analysis more efficiently, thereby improving the efficiency and quality of scientific research.

Yanyin Technology was established in October 2023, dedicated to building a next-generation digital R&D collaboration platform for biopharmaceuticals to enhance research and development efficiency. The founding team of Yanyin Technology comprises senior executives from SAP, a Fortune 500 company, and Ph.D. holders from Harvard Medical School. The company’s vision is to create a research cloud that connects the biopharmaceutical ecosystem and to build China’s largest scientific research community.

Yanyin Zhiyan Cloud focuses on providing AI-powered research collaboration platforms and solutions for the biomedical and pharmaceutical sector, offering Academic (free), Professional, and Enterprise editions. The company aims to help 100,000 on-campus researchers and scientific investigators in the biomedical field use licensed molecular biology tools through its Academic (free) and Professional editions over the next few years, while empowering 1,500 innovative pharmaceutical companies across China with a cost-effective research collaboration platform through its Enterprise edition.

With the completion of this financing round, Yanin Technology will invest in product R&D to build the next-generation Yanin Zhiyan Cloud 2.0. Leveraging large AI models for biomedicine and collaborating with leading AI partners in the industry, the company will jointly develop intelligent biomedical applications, such as AI-powered literature analysis, a Biomedical Co-Pilot, 3D protein structure prediction, and intelligent experimental design. By utilizing artificial intelligence and big data analytics to monitor key data and indicators affecting experimental progress, the platform generates experimental insights that help researchers conduct efficient simulations, thereby making biomedical R&D more efficient and rapid.

Yanyin Technology’s core team possesses extensive experience in biopharmaceuticals and digital R&D. Dr. Chen Zeping, the company’s founder and CEO, previously held senior executive positions at enterprises such as SAP and Taimei Medical Technology, helping more than 200 biopharmaceutical companies achieve digital transformation. His academic research focuses on the interdisciplinary fields of bio-genetic engineering and artificial intelligence, driving the company’s deep development within the industry. Shi Huihui, Co-founder and CTO, formerly worked at SAP and ConvertLab, leading his team to develop products from scratch and serve hundreds of leading industry clients. Core team members graduated from prestigious institutions including Harvard University, the School of Life Sciences at Tsinghua University, the School of Computer Science at Shanghai Jiao Tong University, and the College of Software Engineering at Tongji University, with each member having over ten years of professional experience in the biopharmaceutical and technology sectors.

Dr. Chen Zeping, Founder and CEO of Yanin Technologystated: “We sincerely appreciate the trust and support of our investors. We are committed to building China’s leading digital R&D collaboration platform for biomedicine, serving as a connector within the biomedical research ecosystem. Currently, our team is focused on providing a next-generation AI-powered scientific research collaboration platform for the biomedical sector. This includes Zhiyan Molecule (gene editing platform), Zhiyan Notes (electronic laboratory notebook), Zhiyan Data (scientific big data platform), and Zhiyan Literature (AI large model library), aimed at enhancing the efficiency and quality of scientific research for universities, research institutions, and innovative pharmaceutical companies across China.”

Dr. Kan Chen, Partner at Qiming Venture PartnersQiming Venture Partners stated, “We have consistently maintained a strong focus on innovative enterprises in the biopharmaceutical sector. By leveraging cutting-edge digital technologies and large biopharmaceutical models to build a collaborative digital R&D platform, Yanyin Technology has significantly enhanced the efficiency of research and development experiments for biopharmaceutical companies. The founding team combines expertise in both ‘technology’ and ‘pharmaceuticals,’ bringing extensive experience in business operations and corporate management. We look forward to Yanyin Technology’s contributions in reducing costs and improving efficiency for pharmaceutical R&D, thereby driving genuine improvements in industry-wide productivity.”

Qiming Venture Partners, established in 2006, has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore.

Currently, Qiming Venture Partners manages 11 US dollar funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in sectors such as Technology and Consumer (T&C) and Healthcare.

To date, Qiming Venture Partners has invested in more than 530 high-growth innovative companies. Among these, over 200 have either gone public on exchanges such as the New York Stock Exchange (NYSE), NASDAQ, the Hong Kong Stock Exchange (HKEX), the Shanghai Stock Exchange (SSE), and the Shenzhen Stock Exchange (SZSE), or exited through mergers and acquisitions. More than 70 of these portfolio companies have become industry-recognized unicorns or super unicorns.